181 related articles for article (PubMed ID: 38231514)
1. Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial Cancer.
Zheng S; Donnelly ED; Strauss JB
JAMA Netw Open; 2024 Jan; 7(1):e2351906. PubMed ID: 38231514
[TBL] [Abstract][Full Text] [Related]
2. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
3. Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.
Zheng S; Cao Y; Randall J; Yu H; Thomas TO
Thorac Cancer; 2023 Aug; 14(23):2269-2274. PubMed ID: 37345618
[TBL] [Abstract][Full Text] [Related]
4. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
[TBL] [Abstract][Full Text] [Related]
6. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
[TBL] [Abstract][Full Text] [Related]
7. A cost-effective, machine learning-based new unified risk-classification score (NU-CATS) for patients with endometrial cancer.
Zheng S; Wu Y; Donnelly ED; Strauss JB
Gynecol Oncol; 2023 Aug; 175():97-106. PubMed ID: 37336081
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
[TBL] [Abstract][Full Text] [Related]
9. POLE/POLD1 mutation and tumor immunotherapy.
Ma X; Dong L; Liu X; Ou K; Yang L
J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
[TBL] [Abstract][Full Text] [Related]
10. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
Magrin L; Fanale D; Brando C; Fiorino A; Corsini LR; Sciacchitano R; Filorizzo C; Dimino A; Russo A; Bazan V
Oncogene; 2021 Oct; 40(40):5893-5901. PubMed ID: 34363023
[TBL] [Abstract][Full Text] [Related]
11. The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management.
Palles C; Martin L; Domingo E; Chegwidden L; McGuire J; Cuthill V; Heitzer E; ; Kerr R; Kerr D; Kearsey S; Clark SK; Tomlinson I; Latchford A
Fam Cancer; 2022 Apr; 21(2):197-209. PubMed ID: 33948826
[TBL] [Abstract][Full Text] [Related]
12. Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan.
Monsur M; Yamaguchi M; Tashiro H; Yoshinobu K; Saito F; Erdenebaatar C; Li C; Iwagoi Y; Ohba T; Iyama KI; Katabuchi H
Med Mol Morphol; 2021 Jun; 54(2):133-145. PubMed ID: 33399963
[TBL] [Abstract][Full Text] [Related]
13. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN; Briggs SE; Palles C; Domingo E; Kearsey SJ; Grimes JM; Gorman M; Martin L; Howarth KM; Hodgson SV; ; Kaur K; Taylor J; Tomlinson IP
Hum Mol Genet; 2013 Jul; 22(14):2820-8. PubMed ID: 23528559
[TBL] [Abstract][Full Text] [Related]
14. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance.
Bellido F; Pineda M; Aiza G; Valdés-Mas R; Navarro M; Puente DA; Pons T; González S; Iglesias S; Darder E; Piñol V; Soto JL; Valencia A; Blanco I; Urioste M; Brunet J; Lázaro C; Capellá G; Puente XS; Valle L
Genet Med; 2016 Apr; 18(4):325-32. PubMed ID: 26133394
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
[TBL] [Abstract][Full Text] [Related]
16. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
[TBL] [Abstract][Full Text] [Related]
17. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1.
Buchanan DD; Stewart JR; Clendenning M; Rosty C; Mahmood K; Pope BJ; Jenkins MA; Hopper JL; Southey MC; Macrae FA; Winship IM; Win AK
Genet Med; 2018 Aug; 20(8):890-895. PubMed ID: 29120461
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis.
He Y; Wang T; Li N; Yang B; Hu Y
Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
